Výsledky vyhledávání

Akademický článek

A Single- and Multiple-Dose, Multicenter Study of Etelcalcetide in Japanese Hemodialysis Patients With Secondary Hyperparathyroidism

Autor: Keitaro Yokoyama, Masafumi Fukagawa, Takashi Shigematsu, Takashi Akiba, Akifumi Fujii, Akinori Yamauchi, Motoi Odani, Tadao Akizawa

Publikováno v: Kidney International Reports, Vol 2, Iss 4, Pp 634-644 (2017)

The pharmacokinetics, pharmacodynamics, and safety and tolerability profile of etelcalcetide (ONO-5163/AMG 416), a novel, i.v., long-acting calcium-sensing receptor agonist, were studied in Japanese hemodialysis patients with secondary hyperparathyro

Externí odkaz: https://doaj.org/article/08404379244441e88d3a14ecd0f7ec8d

Zobrazit plný text záznamu

Bayesian Hierarchical Modeling and Biomarker Cutoff Identification in Basket Trials

Autor: Satoru Fukimbara, Zhao Yang, Guosheng Yin, Motoi Odani

Publikováno v: Statistics in Biopharmaceutical Research. 13:248-258

Patients’ heterogeneity poses a fundamental problem in the rapidly developing field of precision medicine. Based on a prespecified cutoff, biomarker-based designs provide a flexible approach to sel...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::815bf07b2b60e4d496e8c6e93fb51e5a
https://doi.org/10.1080/19466315.2020.1811146

Zobrazit plný text záznamu

Effects of the Intravenous Calcimimetic Etelcalcetide on Bone Turnover and Serum Fibroblast Growth Factor 23: Post Hoc Analysis of an Open-label Study

Autor: Motoi Odani, Keitaro Yokoyama, Tadao Akizawa, Akifumi Fujii, Takashi Shigematsu, Masafumi Fukagawa, Takashi Akiba

Publikováno v: Clinical Therapeutics. 40:2099-2111

Purpose Secondary hyperparathyroidism (SHPT) is a serious complication that increases the risk of bone disorders in patients with chronic kidney disease (CKD) undergoing hemodialysis. Etelcalcetide is the first injectable calcimimetic approved for tr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f126e586110c287816788e58d7837cb2
https://doi.org/10.1016/j.clinthera.2018.10.016

Zobrazit plný text záznamu

A Single- and Multiple-Dose, Multicenter Study of Etelcalcetide in Japanese Hemodialysis Patients With Secondary Hyperparathyroidism

Autor: Motoi Odani, Keitaro Yokoyama, Takashi Akiba, Tadao Akizawa, Takashi Shigematsu, Masafumi Fukagawa, Akinori Yamauchi, Akifumi Fujii

Publikováno v: Kidney International Reports, Vol 2, Iss 4, Pp 634-644 (2017)
Kidney International Reports

Introduction The pharmacokinetics, pharmacodynamics, and safety and tolerability profile of etelcalcetide (ONO-5163/AMG 416), a novel, i.v., long-acting calcium-sensing receptor agonist, were studied in Japanese hemodialysis patients with secondary h

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d6af77ab0ef80ce9a6feabc111634131
http://www.sciencedirect.com/science/article/pii/S2468024917300414

Zobrazit plný text záznamu

Pharmacokinetics, Pharmacodynamics, and Safety of Nivolumab in Patients With Sepsis-Induced Immunosuppression: A Multicenter, Open-Label Phase 1/2 Study

Autor: Shigeto Oda, Tatsuaki Okamura, Motoi Odani, Tomohiro Harada, Yasuyuki Kakihana, Osamu Nishida, Eizo Watanabe

Publikováno v: Shock (Augusta, Ga.)

Background: Sepsis often induces an immunosuppressive state, which is associated with high mortality rates. Immunostimulation may be beneficial for sepsis. We investigated the pharmacokinetics, pharmacodynamics, and safety of nivolumab, a human progr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8d629de704d7cfb443bcc46d777278d1
https://pubmed.ncbi.nlm.nih.gov/31513050

Zobrazit plný text záznamu

Long-term effects of etelcalcetide as intravenous calcimimetic therapy in hemodialysis patients with secondary hyperparathyroidism

Autor: Takashi, Shigematsu, Masafumi, Fukagawa, Keitaro, Yokoyama, Takashi, Akiba, Akifumi, Fujii, Motoi, Odani, Tadao, Akizawa, T, Otsubo

Publikováno v: Clinical and experimental nephrology. 22(2)

Secondary hyperparathyroidism (SHPT) is a serious major complication in hemodialysis patients with chronic kidney disease. Long-term maintenance of serum phosphate, calcium, and parathyroid hormone (PTH) levels in appropriate ranges in these patients

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e5ec4438b9d3cf19ed2119af93785208
https://pubmed.ncbi.nlm.nih.gov/28836058

Zobrazit plný text záznamu

A phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of etelcalcetide (ONO-5163/AMG 416), a novel intravenous calcimimetic, for secondary hyperparathyroidism in Japanese haemodialysis patients

Autor: Masafumi Fukagawa, Keitaro Yokoyama, Motoi Odani, Takuto Kuramoto, Takashi Akiba, Tadao Akizawa, Akifumi Fujii, Takashi Shigematsu

Publikováno v: Nephrology Dialysis Transplantation

Background Secondary hyperparathyroidism (SHPT) is a major complication associated with chronic kidney disease. We evaluated the efficacy and safety of etelcalcetide (ONO-5163/AMG 416), a novel intravenous calcimimetic, in Japanese haemodialysis pati

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cd76ec7c45b8e58fd55d644985fba3a6
https://pubmed.ncbi.nlm.nih.gov/28057872

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání